Objective-To examine the association between liver fat content and very low-density lipoprotein (VLDL)-apolipoprotein (apo) B-100 kinetics and the corresponding responses to weight loss in obese subjects. Methods and Results-VLDL-apoB-100 kinetics were assessed using stable isotope tracers, and the fat content of the liver and abdomen was determined by magnetic resonance techniques in 25 obese subjects. In univariate analysis, liver fat content was significantly (PϽ0.05 in all) associated with body mass index (rϭ0.65), visceral fat area (rϭ0.45), triglycerides (rϭ0.40), homeostasis model assessment score (rϭ0.40), VLDL-apoB-100 concentrations (rϭ0.44), and secretion rate (rϭ0.45). However, liver fat content was not associated with plasma concentrations of retinol-binding protein 4, fetuin A, adiponectin, interleukin-6, and tumor necrosis factor-␣. Of these 25 subjects, 9 diagnosed as having nonalcoholic fatty liver disease (which is highly prevalent in obese individuals and strongly associated with dyslipidemia) underwent a weight loss program. The low-fat diet achieved significant reduction in body weight, body mass index, liver fat, visceral and subcutaneous fat areas, homeostasis model assessment score, triglycerides, VLDL-apoB-100 concentrations, and VLDL-apoB-100 secretion rate. The percentage reduction of liver fat with weight loss was significantly associated with the corresponding decreases in VLDL-apoB-100 secretion (rϭ0.67) and visceral fat (rϭ0.84). Key Words: obesity Ⅲ liver fat Ⅲ lipoprotein metabolism Ⅲ weight loss Ⅲ cardiovascular disease T he spectrum of nonalcoholic fatty liver disease (NAFLD) includes benign lipid accumulation in the liver (simple steatosis) through to steatohepatitis, fibrosis, and cirrhosis. 1 The prevalence of NAFLD in the general population is up to 30%; however, it is much higher among individuals with type 2 diabetes mellitus and obesity, 2 key features of metabolic syndrome. 2 NAFLD is strongly associated with dyslipidemia, particularly hypertriglyceridemia, which may contribute to the increased risk of cardiovascular disease in these subjects. 3 The underlying mechanism for hypertriglyceridemia in obesity chiefly relates to the oversecretion of triglyceride-rich lipoproteins, particularly very low-density lipoprotein (VLDL) particles. 4 These abnormalities may contribute to central obesity and insulin resistance.
T he spectrum of nonalcoholic fatty liver disease (NAFLD) includes benign lipid accumulation in the liver (simple steatosis) through to steatohepatitis, fibrosis, and cirrhosis. 1 The prevalence of NAFLD in the general population is up to 30%; however, it is much higher among individuals with type 2 diabetes mellitus and obesity, 2 key features of metabolic syndrome. 2 NAFLD is strongly associated with dyslipidemia, particularly hypertriglyceridemia, which may contribute to the increased risk of cardiovascular disease in these subjects. 3 The underlying mechanism for hypertriglyceridemia in obesity chiefly relates to the oversecretion of triglyceride-rich lipoproteins, particularly very low-density lipoprotein (VLDL) particles. 4 These abnormalities may contribute to central obesity and insulin resistance.
Hepatic accumulation of lipids (ie, triglyceride and cholesteryl ester) may perturb VLDL-apolipoprotein (apo) B-100 metabolism in insulin-resistant obese subjects, sufficient to account for hypertriglyceridemia. However, the precise mechanisms responsible for the close relationship between NAFLD and metabolic syndrome remain uncertain. Visceral fat accumulation markedly increases the flux of free fatty acids (FFAs) in the portal vein to the liver. This stimulates hepatic gluconeogenesis and triglyceride synthesis; it also impairs hepatic extraction of insulin. 5 Hepatic insulin resistance also attenuates hepatic lipogenesis and gluconeogenesis, thereby increasing triglyceride accumulation and subsequent VLDL secretion. 6 The accumulation of intrahepatic fat per se also stimulates VLDL secretion by providing a source of fatty acids for the packaging and processing of VLDL. 7 However, a direct link between intrahepatic fat and VLDL-apoB-100 metabolism has not yet been conclusively demonstrated in patients with obesity.
Recently, there has been intense interest in the potential impact of adipocytokines (eg, adiponectin and retinol-binding protein 4 ) and other inflammatory mediators on glucose and lipid metabolism and their contribution to the pathogenesis of NAFLD and hepatic inflammation. 2, 8 However, the precise role of these mediators in modulating the association between intrahepatic fat and VLDL-apoB-100 metabolism remains to be elucidated.
In the present study, we used a stable isotope technique to test the hypothesis that increased intrahepatic fat content is associated with oversecretion of VLDL-apoB-100 in subjects with visceral obesity. We also explored these relationships before and after a period of moderate weight loss.
Methods

Subjects
A total of 25 nonsmoking, centrally obese, white subjects (15 men and 10 women) consuming weight-maintaining diets ad libitum were recruited for the study. None of the subjects had diabetes mellitus (excluded by an oral glucose tolerance test result), the apo E2/E2 genotype, macroproteinuria, creatinemia (Ͼ120 mol/L), hypothyroidism, or abnormal liver enzyme levels. No subject consumed more than 20 g/d of alcohol. There was also no report of a history of cardiovascular disease. Finally, no subject was taking medication or other agents known to affect lipid metabolism. The study was approved by the Ethics Committee of Royal Perth Hospital, and informed consent was obtained before the study was started.
Clinical Protocols
All subjects were admitted to the metabolic ward in the morning after a 14-hour fast. They were studied in a semirecumbent position and allowed to drink only water. A venous blood sample was collected for measurements of biochemical analytes. Arterial blood pressure was recorded after 3 minutes in the supine position using a monitor (Dinamap1846 SX/P; Critikon Inc, Tampa, Fla). Dietary intake was assessed for energy and major nutrients using at least two 24-hour dietary diaries and subsequently analyzed using computer software (DIET 4 Nutrient Calculation Software; Xyris Software, Queensland, Australia). Body composition was estimated at rest in the supine position using an analyzer (Holtain Body Composition Analyser; Holtain Ltd, Dyfed, Wales) from which total body fat and fat-free mass (FFM) were derived; FFM was calculated using the following formula by Lukaski et al 9 : FFMϭ(0.85ϫ[H 2 /Z])ϩ3.04, where H is height (in centimeters) and Z is impedance. For this measure, subjects were asked to fast overnight and to refrain from alcoholic beverages for 24 hours; they were then studied in the morning, after emptying their bladder, in a temperature-controlled room. The technical error for FFM was less than 3%, calculated from 3 repeated measurements by the same operator.
A single bolus of deuterated leucine (d3-leucine), 5 mg/kg of body weight, was administered intravenously within a 2-minute period into an antecubital vein via a 21G butterfly needle. Blood samples were taken at baseline and after injection of the isotope at 5, 10, 20, 30, and 40 minutes and at 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, and 10.0 hours. Subjects were then given a snack and allowed to go home. Additional fasting blood samples were collected in the morning on the following 4 days of the same week (24, 48, 72 , and 96 hours).
Liver and Abdominal Fat Measurements
Proton magnetic resonance spectroscopy was performed with a Sonata 1.5T system (Siemens, Bayswater, Australia). Sequences and quantification procedures for liver fat were described previously. 10 Briefly, a single-volume stimulated echo acquisition mode sequence was used, with parameters for repetition time (1500 milliseconds), echo time (15 milliseconds), voxel size (4ϫ3ϫ4 cm), 7 signal averages, breath holding, and no water saturation; voxels were positioned to avoid hepatic or portal vessels. The manufacturer's magnetic resonance spectroscopy processing software was used to obtain the liver fat to liver water signal ratio, which was converted to liver fat percentage, assuming that the total liver signal equals the fat signal plus the water signal.
Magnetic resonance imaging of 8 transaxial segments (field of view, 40ϫ48 cm; 10-mm thickness) at intervertebral disc levels from T11 to S1 was performed using a 1.0-T scanner (Picker MR; Picker International, Cleveland, Ohio) and a T1-weighted fast-spin echo sequence with a high fat to water signal ratio. Visceral and subcutaneous abdominal adipose tissue areas were measured at vertebra L3.
Diet Intervention
A total of 9 subjects (6 men and 3 women) were selected at random from those with NAFLD, defined as a liver fat content of more than 5%. 11 They entered a weight-reducing hypocaloric diet (low-fat and low-calorie) program for 16 weeks, immediately followed by a 6-week weight stabilization period. For the first 16 weeks of weight loss, a dietitian provided dietary counseling based on calculated basal energy expenditure, from which 2500 kJ was subtracted to estimate the required dietary energy intake. We attempted to maintain the composition of the diet during the end of the study, when the weight stabilization period was similar to that in the run-in phase. All kinetic and imaging procedures were repeated after interventions.
Measurements of VLDL-apo-B100 Enrichments and Calculation of Kinetic Parameters
VLDL was isolated from 2 mL of plasma by ultracentrifugation (Optima XL-100K; Beckman Coulter, Sydney, NSW, Australia) at a density of 1.006. The procedures for isopropanol precipitation, delipidation, hydrolysis, and derivatization of leucine to the oxazolinone derivative were previously described. 12 Plasma-free leucine was also isolated by cation-exchange chromatography using resin (AG 50 W-X8; BioRad, Richmond, Calif) after removing plasma proteins with 60% perchloric acid. Isotopic enrichment was determined using gas chromatography-mass spectrometry, with selected ion monitoring of samples at a mass to charge ratio of 212 (derived from d 3 -leucine) and 209 (derived from unlabeled leucine) and negative ion chemical ionization. Tracer to tracee ratios were derived from isotopic ratios for each sample. The isotopic enrichment of VLDL-apoB-100 after infusion of d 3 -leucine before and after weight loss is shown in Appendix 1. The multicompartmental model used to describe VLDL-apoB100 leucine tracer to tracee ratios were previously described (Appendix 2). 13 The SAAM II program (SAAM Institute, Seattle, Wash) was used to fit the model to the observed tracer to tracee ratios. The fractional catabolic rate (FCR) of VLDL-apoB-100 was derived from the model parameters giving the best fit. Plasma volume was determined after adjusting for the decrease in relative plasma volume associated with an increase in body weight. 14,15 The VLDL-apoB-100 secretion rate was calculated as the product of VLDL-apoB-100 FCR and the corresponding pool size, and expressed as milligrams per kilogram per day.
Biochemical Analytes
All biochemical analyses were measured in samples obtained at baseline. Plasma cholesterol and triglyceride concentrations were determined by standard enzymatic methods (Hitachi, Tokyo, Japan; Roche Diagnostic GmbH, Mannheim, Germany). The high-density lipoprotein cholesterol level was measured by an enzymatic calorimetric method using a commercial kit (Boehringer Mannheim, Mannheim). The LDL cholesterol level was calculated by the Friedewald calculation. Plasma nonesterified fatty acids were measured by an enzymatic colorimetric assay (Wako Pure Chemical, Osaka, Japan). The VLDL-apoB100 concentration was measured using a modification of the method described by Beghin et al. 16 Plasma total apoA-I and apoB-100 concentrations were determined by immunonephelometry (Behring Diagnostics, Kingsgrove, Australia). The plasma insulin level was measured by a solid-phase 2-site sequential chemiluminescent immunometric assay (Diagnostic Products Corporation, Los Angeles, Calif) and a glucose-by-hexokinase method (Hitachi). Insulin resistance was estimated by the homeostasis model assessment (HOMA) score (ie, fasting insulin level [mU/L]ϫfasting glucose level [mmol/L]/22.5). 17 Plasma RBP-4, fetuin A, adiponectin, interleukin 6, and tumor necrosis factor ␣ concentrations were determined using enzyme immunoassay kits (Quantikine, Research & Development Systems, Minneapolis, Minn). Plasma lathosterol and campesterol concentrations were assayed using gas chromatography-mass spectrometry. Genomic DNA was extracted from whole blood, and apoE genotypes were determined using the TaqMan assay on PRISM 7000 sequence detection analyzer (Applied Biosystems, Mulgrave, Victoria, Australia).
All statistical analyses were performed using software (SPSS 15; SPSS Inc, Chicago, Ill). Associations were examined by simple and multivariate linear regression methods. The paired t test was used to determine the impact of weight loss treatment. Statistical significance was defined at the 5% level using a 2-tailed test.
Results
The anthropometric and biochemical characteristics of the 25 middle-aged and normotensive subjects are summarized in Table 1 . Twenty-one subjects had NAFLD as a diagnosis of hepatic steatosis (intrahepatic triglyceride content Ͼ5% of the liver volume). Compared with 15 (9 men and 6 women) nonobese age-and sex-matched subjects, given as meanϮSD (aged 57Ϯ11 years) selected from a previous report, 18 our obese subjects were insulin resistant and mildly dyslipidemic. The 25 obese subjects had a significantly (PϽ0.05 for all) higher VLDL-apoB-100 concentration and secretion rate and a reduced FCR (Appendix 3). The average daily energy and nutrient intake was as follows: 8339Ϯ2190 kJ, 37Ϯ6% energy from fat, 39Ϯ5% energy from carbohydrates, 21Ϯ4% energy from protein, and 3Ϯ3% energy from alcohol. Apo indicates apolipoprotein; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipoprotein; TNF, tumor necrosis factor; VLDL, very low-density lipoprotein.
*Calculated as weight in kilograms divided by height in meters squared. Table 2 shows the correlation between liver fat content and the anthropometric and biochemical characteristics in the subjects studied. In a univariate analysis, liver fat content was significantly (PϽ0.05 for all) and positively associated with body mass index, visceral fat area at vertebra L3, total body fat, energy intake, fat intake, plasma triglycerides, HOMA score, alanine aminotransferase level, and VLDL-apoB-100 concentrations. As shown in Figure 1 , liver fat content was also significantly associated with the VLDL-apoB-100 secretion rate (rϭ0.45, Pϭ0.02). The association between liver fat content and VLDL-apoB-100 secretion rate remained significant (PϽ0.05 for both) after adjusting for dietary fat or carbohydrate intake (rϭ0.45 or rϭ0.44, respectively). Liver fat content was not associated with plasma concentrations of RPB-4, fetuin A, adiponectin, interleukin 6, and tumor necrosis factor ␣ concentrations. In a multiple regression analysis including visceral fat and HOMA score, liver fat content was an independent predictor of the VLDL-apoB-100 secretion rate (␤ coefficient, 0.53; Pϭ0.02). Inclusion of dietary fat or carbohydrate intake instead of visceral fat did not alter the significance of the association between liver fat content and VLDL-apoB-100 secretion rate (␤ coefficient, 0.57; Pϭ0.006). The HOMA score was not significantly (PϾ0.05 for both) associated with the VLDL-apoB-100 secretion rate (rϭ0.04) and the VLDL-apoB-100 FCR (rϭϪ0.27). Similarly, neither fat nor carbohydrate intake was associated with the VLDL-apoB-100 secretion rate (rϭ0.13 and rϭϪ0.28, respectively) and the VLDL-apoB-100 FCR (rϭ0.26 and rϭϪ0.23, respectively). Table 3 shows the dietary composition and nutrient intake of subjects during the study. As noted, the weight loss group participants significantly reduced their total energy and fat and their saturated fat intake, and significantly increased their carbohydrate consumption, during the active weight loss period. Table 4 shows the clinical and biochemical characteristics and the kinetic indexes for VLDL-apoB-100 metabolism after a 16-week dietary intervention in 9 obese subjects with NAFLD. The low-fat diet achieved significant reduction (PϽ0.05) in body weight (Ϫ6%), body mass index (Ϫ6%), and liver (Ϫ29%), visceral (Ϫ18%), and subcutaneous (Ϫ10%) fat areas; total body fat (Ϫ13%); HOMA score (Ϫ15%); triglyceride (Ϫ22%), RBP-4 (Ϫ14%), fetuin (Ϫ40%), and VLDL-apoB-100 (Ϫ22%) concentrations; and the VLDL-apoB-100 secretion rate (Ϫ23%). There was a significant increase (PϽ0.05) in plasma adiponectin concentration (16%). The percentage reduction of liver fat with weight loss was significantly associated with the corresponding changes in the VLDLapoB-100 secretion rate (rϭ0.67) (Figure 2 ) and the visceral fat concentration (rϭ0.84). There was no significant association (PϾ0.05 for all) between the percentage reduction of Liver fat content (%) Liver fat content (%) Figure 1 . Association between the VLDL-apoB-100 secretion rate and liver fat content in 25 obese subjects. 
Correlational Analysis
Weight Loss
Discussion
To our knowledge, we present new evidence in subjects with visceral obesity that elevated liver fat content was predictive of VLDL-apoB-100 oversecretion, and that the reduction of liver fat with weight loss, was significantly associated with a corresponding decrease in VLDL-apoB-100 secretion.
Few studies have examined the association between liver fat content and VLDL-apoB-100 metabolism in obese subjects. Adiels et al 19 reported that liver fat content was significantly associated with the VLDL 1 -apoB-100 secretion Apo indicates apolipoprotein; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipoprotein; TNF, tumor necrosis factor; VLDL, very low-density lipoprotein.
*Data are given as meanϮSEM. Significant differences before and after treatment were compared using paired t tests. †Calculated as weight in kilograms divided by height in meters squared.
rate in nonobese men. In that study, no significant association was found between liver fat content and VLDL-apoB-100 secretion rate in 10 type 2 diabetic men who were treated with diet and/or antidiabetic medication. The insulin-sensitizing effect of such diabetic treatments might have confounded the association between liver fat content and VLDL-apoB-100 secretion in these subjects. Fabbrini et al 20 found that liver fat content was significantly associated with VLDL-triglyceride secretion, but not with VLDL-apoB-100 secretion, in obese subjects, most of whom were women; however, they did not study these associations after weight loss. In contrast, we found that liver fat content was significantly associated with VLDL-apoB-100 secretion; however, we mostly studied obese men and the effects of weight loss on hepatic fat and VLDL-apoB-100 secretion. In women, the liver secretes less but more triglyceride-enriched VLDL particles than men. 21 There could be a sex difference in the impact of hepatic fat content on the relative secretion of VLDL-apoB-100 and triglycerides by the liver; this requires further investigation. The liver fat content reflects the balance between FFA flux to the liver, de novo lipogenesis, and diet on the one hand and fatty acid oxidation and triglyceride export on the other hand. 7 Intra-abdominal adipocytes are lipolytically active, and visceral fat accumulation in individuals with central obesity results in markedly increased flux of FFAs in the portal vein to the liver; this can stimulate de novo lipogenesis. 5 Hepatic insulin resistance also upregulates the expression of sterol regulatory element-binding protein 1c and leads to activation of key enzymes for lipogenesis. 6, 22 The increased uptake of dietary cholesterol not only activates liver X receptor ␣, but also the gene expression for de novo lipogenesis. 22 The net effect of these processes is increased accumulation of fat in the liver, which may subsequently drive the oversecretion of VLDL-apoB-100. Consistent with this notion, we found that liver fat content was significantly associated with visceral fat, insulin resistance, dietary fat (or total energy) intake, and the VLDL-apoB-100 secretion rate. A prolonged fasting state (Ͼ36 hours) could potentially increase FFA release from adipose tissue and delivery to the liver, thereby stimulating triglyceride synthesis and affecting hepatic fat and VLDL-apoB-100 secretion. 23 However, there is evidence that VLDL-triglyceride and VLDL-apoB-100 concentrations remain steady within a 20-hour period of fasting, 24 implying that our intermediate term of fasting used in the stable isotope study does not affect hepatic fat content or assembly and secretion of VLDL-apoB-100. We did not observe a significant association between liver fat content and plasma nonesterified fatty acid concentration, suggesting that systemic nonesterified fatty acid concentration may not necessarily reflect portal FFA flux to the liver. Also, we could not fully exclude the possibility that the observed association between liver fat content and VLDL-apoB-100 secretion is secondary to the overall effects of visceral fat, insulin resistance, or increased dietary fat intake on VLDL transport. However, we found that liver fat content remained a significant predictor of the VLDL-apoB-100 secretion rate in regression models that included these metabolic and dietary variables. These data suggest that liver fat content could play an important role in trafficking various sources of fatty acids for the packaging and processing of VLDL. Interestingly, Charlton et al 25 found that subjects with nonalcoholic steatohepatitis, an advanced form of NAFLD, had reduced apoB-100 secretion. Although the mechanism is unknown, the researchers concluded that reduced apoB synthesis is a determinant of the development of hepatic steatosis. However, it is possible that changes in the structural integrity and chemical function of hepatocytes in subjects with nonalcoholic steatohepatitis are likely to interfere with the apoB secretory pathway. By increasing hepatic endoplasmic reticulum stress, increased FFA supply to the liver may paradoxically decrease apoB-100 secretion 26 ; however, the contribution of this mechanism to our principal findings in subject with mild steatosis remains conjectural.
The development of inflammation and fibrosis in NAFLD mainly involves 2 stages, the so-called 2-hit hypothesis. 27 Hepatic fat accumulation represents the "first hit"; and insulin resistance, oxidative stress, and increased cytokine release induce the "second hit." RBP-4, fetuin-A, and adipocytokines have all been implicated in the second hit for the development of inflammation and fibrosis in subjects with NAFLD. However, none of these markers was associated with liver fat content in our study. The reason for this remains unclear. It is likely that our nondiabetic obese subjects are in the early stage of NAFLD and that the impact of these metabolic factors might be secondary to other factors, such as obesity, dietary intake, and insulin resistance. Weight loss by dietary restriction is the most common approach to correct NAFLD and dyslipidemia. 28 It has 3 potential effects that may reduce the hepatic availability of fatty acids for triglyceride storage and export. Weight loss reduces the release of FFAs from visceral fat to the liver. It also improves insulin sensitivity, thereby potentially impeding de novo lipogenesis. Consistent with the notion, we found that weight loss effectively reduces visceral fat and improves insulin sensitivity, leading to a significant reduction in liver fat content. Previously, in obese men, we demonstrated that intensive weight loss (Ͼ10% of body weight) with a low-fat and low-calorie diet resulted in a greater reduction in visceral fat mass (Ϫ27%) and hepatic VLDL-apoB-100 secretion (Ϫ50%) than in the present study; the change in visceral fat was also significantly correlated with the change in hepatic VLDL-apoB-100 secretion. 29 We did not confirm this association, probably owing to differences in the degree of weight loss between the 2 studies. In this study, we also specifically selected subjects with NAFLD and tested the association between liver fat content and VLDL-apoB-100 secretion with weight loss. We only observed a significant relationship between changes in VLDL-apoB-100 secretion and liver fat content, but not changes in visceral fat, insulin resistance, or dietary intake. These data further support a more direct role for liver fat content in the regulation of VLDL transport, consistent with our earlier correlation findings. The existence of a weaker correlation between changes in liver fat content and the VLDL-apoB-100 secretion rate after adjusting for changes in visceral fat, insulin resistance, lathosterol, or dietary fat intake probably reflects the impact of these metabolic and dietary factors on VLDL transport, consistent with a complex relationship among metabolic risk factors in patients with NAFLD. Despite our findings that weight loss reduced VLDL-apoB-100 FCR by 20%, the difference was not significant (Pϭ0.36). The lack of effect of weight loss on VLDL-apoB-100 FCR is consistent with previous studies. 29, 30 Changes in body fat, dietary intake, visceral fat, HOMA score, and adipocytokines were also not correlated with VLDL-apoB-100 FCR.
Our study does have limitations. Our weight loss study was not a controlled observation. However, it provides evidence to support the direct relationship between liver fat content and the VLDL-apoB-100 secretion rate. As in previous protocols, 29, 30 we did not use a control dietary period before the first isotope study to avoid alternating the nutritional steady state. On this ad libitum diet, there were no significant associations at stable body weight at baseline between either VLDL-apoB-100 secretion or liver fat content and nutrient intake. We did not perform liver biopsies and, therefore, cannot make inferences concerning steatohepatitis before and after weight loss; however, the short-term duration of weight loss is unlikely to influence hepatic fibrosis. We did not measure plasma volume directly, which could affect the calculation of the VLDL-apoB-100 secretion rate. However, our method for estimating plasma volume from body weight has been well validated against more direct methods for measuring plasma volume. 14, 15 The sample size in this study was small. Therefore, the findings need to be confirmed in a larger sample size.
Our kinetic findings could be clinically important. NAFLD is a common feature of lipid disorders, seen in insulin-resistant and centrally obese subjects. Our kinetic studies of VLDL-apoB-100 metabolism provide new knowledge of the underlying mechanisms of how liver fat is responsible for hypertriglyceridemia in central obesity. Our data support the role of liver fat as the driver of VLDL-apoB-100 secretion and highlight the importance of therapies that regulates NAFLD in the management of dyslipidemia and cardiovascular risk. We found that a reduction in liver fat with a moderate weight reduction may account for reduced VLDLapoB-100 secretion and plasma concentration. These effects appear to be independent of inflammatory mediators of NAFLD. Given that liver fat content may also play an important role in other triglyceride-rich lipoprotein pathways (such as fatty acid and VLDL-triglyceride metabolism), further studies should examine these pathways and explore the effect of other agents (such as fibrates, fish oils, insulin sensitizers, and cholesterol absorption inhibitors) alone or added to weight loss on liver fat content and the kinetics of triglyceride-rich lipoproteins in these subjects.
